Last reviewed · How we verify
SHR-A1811 and capecitabine
SHR-A1811 and capecitabine is a Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | SHR-A1811 and capecitabine |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (PHASE2)
- SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study (PHASE2)
- Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (PHASE2)
- A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane (PHASE3)
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (PHASE2)
- SNF Platform Study of HR+/ HER2-advanced Breast Cancer (PHASE2)
- A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-A1811 and capecitabine CI brief — competitive landscape report
- SHR-A1811 and capecitabine updates RSS · CI watch RSS
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about SHR-A1811 and capecitabine
What is SHR-A1811 and capecitabine?
SHR-A1811 and capecitabine is a Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd..
Who makes SHR-A1811 and capecitabine?
SHR-A1811 and capecitabine is developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (see full Suzhou Suncadia Biopharmaceuticals Co., Ltd. pipeline at /company/suzhou-suncadia-biopharmaceuticals-co-ltd).
What development phase is SHR-A1811 and capecitabine in?
SHR-A1811 and capecitabine is in Phase 2.